Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines without preservatives, which completed phase III clinical trials; and human H5N1 influenza vaccine that completed pre-clinical studies. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.

Company Data

Name Chengdu Kanghua Biological Products Co., Ltd.

Company Chengdu Kanghua Biological Products Co., Ltd.

Website https://www.kangh.com

Primary Exchange

SHENZHEN STOCK EXCHANGE

ISIN CNE100003Y57

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Wennian Wu

Market Capitalization 11 Mrd.

Country China

Currency CNY

Employees 0,6 T

Address No. 182, Beijing Road, 610100 Chengdu

IPO Date 2020-06-16

Ticker Symbols

Name	Symbol
SHENZHEN STOCK EXCHANGE	300841.SZ

More Shares

Investors who hold Chengdu Kanghua Biological Products Co., Ltd. also have the following shares in their portfolio:

Horizon Technology Finance Corporation 6.25% NT 22 ETF

Restaurant Brands Asia Limited Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog